Potential for parenthood is good for adult female survivors of Hodgkin lymphoma

Share this content:

the ONA take:

A prospective, longitudinal study involving 590 female patients younger than 18 years at diagnosis who participated in one of five Hodgkin lymphoma treatment studies between June 19, 1978, and July 12, 1995, were the cohort in a study to assess the frequency for parenthood in female survivors of Hodgkin lymphoma. Parenthood was defined as delivery of a liveborn child.

The control group was the German female population age 16-49 years, using data from the 2012 Mikrozensus population survey.

Of the 590 patients in the cohort, 467 had long-term follow-up (median 20.4 years) and were in continuous remission. Of these patients, 228 patients had 406 children.

Cumulative incidences of parenthood were 67% at 27.7 years follow-up (longest period of follow-up at birth of first child) and 69% at age 39.8 years (oldest age of patient at birth of first child).

Parenthood was significantly lower among survivors who received pelvic radiation compared with those who received abdominal and supradiaphragmatic radiation, and parenthood in women age 40-44 years at the time of last information was lower than in women the same ages in the general population.

The results indicate a favorable prognosis for parenthood in female survivors of Hodgkin lymphoma. The researchers suggest counseling for female survivors should include this positive potential for future parenthood.

Young adult leukemia, lymphoma survivors more distressed than older survivors
Parenthood was significantly lower among Hodgkin lymphoma survivors who received pelvic radiation.
We aimed to assess the frequency of parenthood in female survivors of Hodgkin's lymphoma younger than 18 years at diagnosis, and to compare it with that in a female population control group.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs